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I Introduction
For more than 20 years, the European information 
network on drugs and drug addiction (Reitox), 
has been the cornerstone of the European drug 
monitoring and reporting system, to which it 
contributes by collecting, analysing, interpreting 
and disseminating data at national level, as well 
as by defining the tools for monitoring. Reitox is 
a partner and an integral part of the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), a key player at EU and international 
level. The Reitox network currently includes the  
28 EU Member States plus Turkey, Norway and the 
European Commission.
Each year many research projects from all over 
the EU contribute to an improved understanding 
of the drug phenomenon. Reitox, together with 
the EMCDDA, systematically links information 
coming from research, policy and law enforcement, 
resulting in a comprehensive picture of the EU drug 
situation. This broad scope requires well-defined 
strategic goals and appropriate analytical and 
reporting tools to combine heterogeneous data into 
a full picture. 
I Reitox network mandate
The Reitox is a mandated network type, managed 
by the EMCDDA. Collectively, the focal points are 
responsible for the majority of the EU drug-related 
data collection and the development of harmonised 
data collection tools in various areas. Besides 
monitoring, the Reitox focal points, among other 
responsibilities, promote best practices and play a 
key role at national level, such as contributing to the 
evaluation of national drug strategies (Figure 1).
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I Reitox development  
   framework
The EMCDDA 2025 strategy, endorsed in 2016, 
aims at contributing to a healthier and more secure 
Europe. In this context, Reitox is currently defining 
the new strategic goals for the network as a whole 
and how these will be operationalised and achieved 
(Figure 3).  
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The appointment, setting up, functioning and 
maintenance of a national focal point is the 
responsibility of the national authorities  
(Figure 2). Twice a year, the EMCDDA organises 
meetings for the heads of national focal points to 
discuss and endorse data collection tools, reporting 
requirements for the upcoming reporting cycle and 
to further develop and consolidate the network 
and its members. Reitox is also represented on 
the EMCDDA’s Management Board and in the 
EMCDDA’s Scientific Committee, ensuring that the 
network participates in the agency’s main strategic 
and scientific developments.
FIGURE 3 | Reitox development framework and the EMCDDA 
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In the face of an evolving drug situation, the 
EMCDDA, together with Reitox, recognises the 
need to ensure that the tools used to measure drug 
use and its public health consequences remain fit 
for purpose. Work is also needed to further develop 
the tools used to observe changes in the drug 
markets and other areas threatening the security of 
EU citizens.
The way forward for Reitox is to review and update 
its priorities and consolidate them in a new ‘Reitox 
development framework’. At stake will be the 
sustainability, effectiveness and future evolution of 
the network, taking into account all the priorities of 
the members of Reitox and of their customers.
Reitox in focus
 Reitox stands for Réseau Européen  
 d’Information sur les Drogues et les  
 Toxicomanies
 1995: 15 national focal points (NFPs) from EU   
 Member States
 2017: 30 national focal points: 28 EU Member   
 States, Norway and Turkey, and European  
 Commission 
 Maintain 30 national focal points websites with  
 the newest data on drug situation in 24 national  
 languages 
 Deliver annually to the EMCDDA: 900 statistical  
 tables and 300 thematic workbooks
 NFPs are involved in cooperation projects  
 with the Western Balkan countries, the Southern  
 and Eastern EU neighbouring countries, Central  
 Asian countries and Latin America and  
 Caribbean countries; 
 Share expertise in EU or national research  
 projects, in evaluation of drug strategies among  
 many others
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FIGURE 1 | National focal points: heart of network 
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